Cureus . Major Thrombotic Event Despite Anticoagulation in a Patient With COVID-19

[tetano]

Cureus


. 2020 Jun 29;12(6):e8896.
doi: 10.7759/cureus.8896.
Major Thrombotic Event Despite Anticoagulation in a Patient With COVID-19


Basma Ataallah ^{1 2} , Aman Sharma ¹ , Sharmiz Tamanna ² , Joseph Ng ³ , Gregory Haggerty ^{4 1}



Affiliations

• PMID: 32742863
• PMCID: PMC7389143
• DOI: 10.7759/cureus.8896

Free PMC article

Abstract

The outbreak of coronavirus disease 2019 (known as COVID-19), which started in Wuhan, China in December 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been associated with both venous and arterial thromboembolism likely secondary to significant cytokine activation and inflammation. Reports on the incidence of thrombotic complications, however, are not well documented. Our case will examine a young man diagnosed with COVID-19 who developed an acute, severe bilateral saddle pulmonary embolism while on prophylactic dose anticoagulation after being admitted to the hospital and treated for two weeks with significant improvement.

Keywords: coagulopathy; covid-19; pulmonary embolism; therapeutic anticoagulation; thrombosis.